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A B S T R A C T
Skeletal muscle is a highly metabolic and dynamic tissue that is formed through the complex and well-organised
process of myogenesis. Although there is a good understanding about the role of the Muscle Regulatory Factors
during myogenesis, little is known about the potential interplay of other metabolic proteins. The aim of this
study was to determine the endogenous mRNA expression profile for a novel group of genes, recently associated
with β2-adrenergic agonist (BA) induced muscle hypertrophy in pigs [1], during myogenic differentiation in
C2C12 cells and their response to dibutyryl cyclic-AMP (dbcAMP). These genes included mitochondrial phos-
phoenolpyruvate carboxykinase (PCK2/PEPCK-M), genes involved in serine biosynthesis (Phosphoglycerate
dehydrogenase, PHGDH; Phosphoserine aminotransferase-1, PSAT1; Phosphoserine phosphatase, PSPH) and
those involved in an integrated stress response (Asparagine synthetase, ASNS; Sestrin-2, SESN2; and Activating
transcription factor-5, ATF5).
A coordinated peak in endogenous PCK2, PHGDH, PSAT1, PSPH, ASNS, ATF5 and SESN2 mRNA expression
was observed at day 2 of differentiation (P < 0.001) in C2C12 cells, which coincided with the peak in myogenin
mRNA. Myotube hypertrophy was induced with dbcAMP (1mM) treatment from day 0, thereby mimicking the in
vivo BA response. Although dbcAMP treatment from day 0 induced larger myotubes and increased both myosin
heavy chain-IIB (MyHC-IIB) and pyruvate carboxylase (PC) mRNA, the expression of PCK2, PHGDH, PSAT1 and
ASNS mRNA were all unaffected. Treatment with dbcAMP from day 4 increased MyHC-IIB mRNA, however this
was less dramatic compared to the response observed following treatment from day 0, but there was no effect on
PC mRNA. There was also no effect of dbcAMP treatment from day 4 on PCK2, PHGDH, PSAT1 and ASNS mRNA.
To conclude, the coordinated day 2 peak in endogenous expression of PCK2, PHGDH, PSAT1, PSPH, ASNS,
ATF5 and SESN2 mRNA may relate to a shift in biosynthetic demand required to initiate myogenic differ-
entiation. However, dbcAMP had no effect on the expression of these genes in vitro suggesting that the effects
observed in BA-treated pigs might be via other signalling pathways from the activation of the β2-adrenergic
receptor, but independent of cAMP, or that there are species differences in the response.
1. Introduction
Growth promoters, including β2-adrenergic receptor agonists (BA)
and recombinant porcine growth hormone (GH), are used commercially
in Australia, India and the USA to improve livestock feed efficiency [1].
BA and GH are repartitioning agents that increase weight gain by re-
directing nutrients to muscle growth and reducing fat deposition, but
via different mechanisms, which have yet to be fully elucidated [2–4].
We previously compared the effects of Ractopamine (BA) and Reporcin
(GH) administered to growing gilts for up to 27 days on porcine skeletal
muscle transcriptomes to identify mechanistic differences in the re-
sponses [5,6]. GH had a whole-body growth effect and increased liver
weight, whereas BA induced greater increases in muscle weights. Both
BA and GH induced a coordinated upregulation of a novel group of
genes in muscle at day 3, but only BA induced a sustained effect (> 7
days). This novel group of genes included those encoding proteins
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involved in serine biosynthesis (phosphoglycerate dehydrogenase,
PHGDH; phosphoserine aminotransferase-1, PSAT1; phosphoserine
phosphatase, PSPH), a mitochondrial gluconeogenic enzyme (phos-
phoenolpyruvate carboxykinase, PCK2/PEPCK-M) [5] and proteins in-
volved in an integrated stress response (asparagine synthetase, ASNS;
sestrin-2, SESN2; activating transcription factor-5, ATF5; and CCAAT/
enhancer binding protein-γ, CEBPG/C/EBP-γ) [6]. This demonstrated,
for the first time, that coordinated upregulation of this novel group of
genes was associated with hypertrophic growth of terminally differ-
entiated muscle, whereas previous studies had associated upregulation
of PHGDH and PEPCK-M with cancer.
There has been increased interest in the genes involved in the serine
biosynthesis pathway, since PHGDH was observed to be upregulated in
certain breast cancers and reported to be key for cancer cell metabolism
and survival [7–10]. Serine is synthesised from 3-phosphoglycerate, an
intermediate of glycolysis, through a three-step enzymatic process in-
volving PHGDH, PSAT1 and PSPH. Serine plays an important role in
growth and metabolism and can subsequently be used for the synthesis
of amino acids, phospholipids, and nucleotides [11]. The upregulation
of PHGDH indicates that serine biosynthesis is important during times
of high metabolic activity and tumour growth, however little is known
about the role of serine biosynthesis in muscle cell metabolism. Simi-
larly there has been increased interest in the mitochondrial isoform of
phosphoenolpyruvate carboxykinase (PEPCK-M) in recent years as it
too is upregulated in certain cancers [12,13]. Phosphoenolpyruvate
carboxykinase (PEPCK) is a gluconeogenic enzyme involved in the re-
generation of phosphoenolpyruvate from oxaloacetate, but has also
been identified to play a role in glyceroneogenesis, amino acid synthesis
and cataplerosis [14]. There are two genes that encode for the two
PEPCK isoforms: PCK1 encodes for cytosolic PEPCK (or PEPCK-C) and
PCK2 for PEPCK-M. For many years, studies of PEPCK function focussed
on the role of PEPCK-C and the specific role of PEPCK-M was over-
looked, however PEPCK-M has been recently identified as a key reg-
ulator of cancer cell metabolism. Upregulation of PEPCK-M has been
associated with the rewiring of energy metabolism to reroute glycolytic
intermediates into serine biosynthesis in order to sustain cancer cell
growth and survival through the activation of an endoplasmic re-
ticulum stress response [12,15]. PCK2, but not PCK1, was identified in
the same gene cluster as PHGDH, showing the same response profile to
BA treatment in pigs [5]; and a similar mRNA expression profile was
reported for ASNS, ATF5, CEBPG and SESN2 [6], which have all been
linked to an integrated stress response [16,17]. The apparent co-ordi-
nated upregulation of this novel group of genes suggests the possible
transcriptional regulation by a common transcription factor or factors.
A plausible candidate is Activating transcription factor-4 (ATF4), which
forms a heterodimer with C/EBP-γ and regulates the transcription of
various genes, including ASNS, ATF5 and SESN2 [16]. ATF4 has also
been shown to upregulate genes involved in glycolysis, serine bio-
synthesis and amino acid transport, including PHGDH [18] and PCK2
[12], therefore ATF4 or ATF5 could potentially be associated or directly
involved in co-ordinately regulating the transcription of this novel
group of genes.
As mentioned, upregulation of these genes (PHGDH, PCK2, ASNS)
has previously been observed in certain cancers, but we were the first to
report the co-ordinated upregulation and transitional change associated
with hypertrophic growth of terminally differentiated skeletal muscle
[5,6]. The aim of the current study was to characterise the expression
profiles for the novel group of genes (PCK2, PHGDH, PSAT1, PSPH,
ASNS, SESN2, ATF5, CEBPG) during myogenic differentiation in vitro.
Myogenesis is a highly coordinated process that involves the fusion of
mononuclear muscle progenitor cells (myoblasts) to form multi-
nucleated myotubes (in vitro) and muscle fibres (in vivo). The myogenic
regulatory factors (MRFs), Myf5, MyoD, Myogenin and MRF4, are a
family of basic helix-loop-helix transcription factors that are key for the
transcriptional regulation of myogenesis [19] and each is expressed in a
specific pattern [20]. Myf5 is the earliest MRF to be expressed, followed
closely by MyoD [20], and both are essential for proliferation, specifi-
cation and commitment to a muscle cell fate; whereas Myogenin and
MRF4 are expressed later [20], associated with their role in the in-
itiation of myogenic differentiation, leading to upregulation of various
muscle-specific genes and contractile proteins, such as Myosin Heavy
Chain (MyHC) isoforms. Therefore selected myogenesis associated
genes were measured alongside the novel group of genes. The mouse
myoblast C2C12 cell line is often used to model skeletal muscle differ-
entiation in vitro as it provides a robust system that has the capacity to
generate well-established myotube networks [21]. Therefore, we uti-
lised C2C12 cells to perform comprehensive time-course experiments to
study the endogenous mRNA expression profiles for this novel group of
genes, as well as genes associated with myogenesis and skeletal muscle
metabolism. Despite expressing β2-adrenergic receptors (β2-AR), it has
been reported that C2C12 cells do not display a hypertrophic response
to BA treatment [22]. Hence, C2C12 cells were treated with dibutyryl
cyclic AMP (dbcAMP) from day 0 (as differentiation was initiated) or
day 4 of differentiation (terminally differentiated myotubes) to induce
down-stream signalling from the β2-AR and determine the effects on
mRNA expression for the same group of genes.
2. Materials and methods
2.1. Cell culture materials and compounds
High glucose Dulbecco's modified eagle's medium (DMEM),
dbcAMP and cell culture grade water were purchased from Sigma-
Aldrich (Poole, UK) and other cell culture reagents were purchased
from Fisher Scientific (Loughborough, UK). Cell culture grade water
was used to resuspend dbcAMP sodium salt (CAS #: 16980-89-5; LOT
#: SLBJ2610V), filter-sterilised through a 0.2 μm filter and stored in
aliquots at −20 °C. dbcAMP was freshly diluted (1:100) into differ-
entiation media (DM) on each day of treatment.
2.2. Cell culture
C2C12 cells were seeded onto 6-well plates in growth medium
(DMEM supplemented with 10% foetal bovine serum and 1% peni-
cillin/streptomycin) at a density of 1.5× 105 cells per well and cul-
tured as described previously [20]. At day 0 (~80% confluence), cells
were switched to DM (DMEM supplemented with 2% horse serum and
1% penicillin/streptomycin), to induce myogenic differentiation and
DM refreshed every 48 h.
To study endogenous mRNA expression, cells were harvested every
24 h. To investigate the effect of dbcAMP treatment, dbcAMP was di-
luted in DM then added from either day 0 (onset of differentiation) or
day 4 (differentiated myotubes) until the end of each time-course.
Preliminary work determined 1mM as an effective dose of dbcAMP
[23] and cell culture grade water was used as the vehicle control. Cells
were harvested every 12 h or 24 h as appropriate.
2.3. Cell harvest
Medium was removed and cells harvested into 200 μl per well of ice
cold RNase-free phosphate buffered saline at the indicated time-points.
Samples were then stored at −80 °C until RNA extraction was per-
formed. The number of replicate wells harvested per time-point and
treatment varied between n= 3 and 6 (see Results for detail).
2.4. RNA extraction
Samples collected for endogenous mRNA expression were thawed
into 800 μl TRIzol® reagent (Invitrogen, Paisley, UK) at room tem-
perature and gently vortexed, then total RNA was extracted and DNase
treated (Promega, Southampton, UK) as recommended in the manu-
facturer's guide. Total RNA was extracted from dbcAMP study samples
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using the High Pure RNA Isolation Kit (Roche Diagnostics, Mannheim,
Germany) as described previously [20].
2.5. cDNA synthesis
NanodropTM 2000 spectrometer (Thermo Scientific, Wilmington,
USA) was used to quantify RNA concentrations of each sample and then
all samples were diluted to 50 ng/μl. RNA (500 ng) was reverse tran-
scribed into cDNA using random hexamer primers, as supplied in the
Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics,
Mannheim, Germany), for the endogenous mRNA expression study;
whereas RevertAid RT First Strand cDNA Synthesis kit (Thermo
Scientific, Vilnius, Lithuania) was used for the dbcAMP study samples.
In both cases, synthesis of cDNA was performed according to the
manufacturer's guide.
2.6. Real-time quantitative PCR and quantification of total cDNA
All reagents for real-time quantitative PCR (QPCR) were purchased
from Roche Diagnostics (Burgess Hill, UK). QPCR was performed using
SYBR Green reagent to quantify mRNA transcript abundance, as pre-
viously described [20]. QPCR primers were designed using the Mus
musculus genome (GRCm38) and tested in-house by analysis of the melt
curve and gel electrophoresis. QPCR primers used in this study can be
found in Table 1. QPCR primer sequences for myosin heavy chain
(MyHC)-I [24], MyHC-IIB [25], Myf5 and myogenin [20] have been
reported elsewhere. We previously reported [20] the use of OliGreen®
reagent (Life technologies, Oregon, USA) to quantify total cDNA con-
centration and thereby normalise mRNA transcript abundance for each
gene, due to problems in finding suitable reference genes that showed
no changes in expression over the C2C12 differentiation time-course.
2.7. Statistical analyses
For endogenous mRNA expression, one-way analysis of variance
(ANOVA) was performed on normalised data using GraphPad Prism
(7.03) software. Dunnett's multiple comparison test was used when
appropriate (ANOVA P < 0.05) to compare time-points to day 0. For
dbcAMP experiments, two-way ANOVA (time x treatment) was per-
formed on normalised data using Genstat (19th edition), followed by
Bonferroni post-hoc test when appropriate (ANOVA P < 0.05). Data
are presented as means ± standard error of the mean (SEM).
Significance was accepted at P < 0.05. Matrices for Pearson's r corre-
lation coefficients were generated in Microsoft Excel.
3. Results
3.1. Endogenous mRNA expression in C2C12 cells across the time-course of
myogenic differentiation
Early C2C12 myotubes were observed at day 2 of differentiation
that increased in size with time resulting in a large extensive network of
C2C12 myotubes by day 8 of differentiation (Fig. 1a). As we reported
previously [20], Myf5 mRNA was significantly higher in proliferating
C2C12 myoblasts compared to differentiating myotubes (P < 0.001;
Fig. 1b), whereas myogenin mRNA expression was minimal in pro-
liferating myoblasts, then as Myf5 mRNA decreased, myogenin mRNA
increased and peaked between days 1 and 2 of differentiation followed
by a gradual decline thereafter (P < 0.001; Fig. 1c). Similarly, the
mRNA expression of the myosin heavy chain isoforms (MyHC-I and
-IIB) showed similar patterns as those we previously reported [20].
MyHC-I mRNA was upregulated as differentiation was initiated,
showing a similar profile to myogenin (P < 0.001; Fig. 1d), whereas
MyHC-IIB was expressed much later, from day 3 of differentiation
(P < 0.001; Fig. 1e). Relative mRNA expression of isocitrate dehy-
drogenase-2 (IDH2), a mitochondrial enzyme involved in the TCA cycle,
enolase-3 (ENO3), a glycolytic enzyme, and pyruvate carboxylase (PC),
a gluconeogenic enzyme, were determined as indicators of oxidative,
glycolytic and gluconeogenic metabolism respectively. Relative IDH2
mRNA was higher in proliferating myoblasts and decreased with dif-
ferentiation (P < 0.001; Fig. 1f), whereas ENO3 and PC were lower in
proliferating myoblasts and increased in differentiated myotubes (both
P < 0.001; Fig. 1g and h).
A strong positive correlation was observed between Myf5 and IDH2
(r=0.955) but a negative relationship between Myf5 and both ENO3
(r=−0.739) and PC (r=−0.658), which suggests that as C2C12 cells
differentiate they might switch from oxidative-dependent metabolism
to more glycolytic. There were also strong positive correlations between
MyHC-I and ENO3 (r=0.728) and MyHC-IIB and PC (r=0.893).
Pearson's r correlation coefficients are displayed in Table A.1.
Relative mRNA expression levels for PCK2, ASNS, PHGDH, PSAT1
and PSPH were higher in proliferating myoblasts (between days −2
and −1 of differentiation) and decreased in differentiated myotubes
from day 4 onwards (all P < 0.001; Fig. 2a-e). In contrast, SESN2 and
ATF5 showed similar mRNA levels in proliferating myoblasts and dif-
ferentiated myotubes, but there was a significant effect of time, due to
increased expression at day 2 of differentiation (both P < 0.001;
Fig. 2f and g). Interestingly, a peak in endogenous mRNA expression
was observed at day 2 of differentiation for all 7 genes, which coincided
with the peak in myogenin mRNA, suggesting a potential coordinated
role in myogenic differentiation. In contrast, relative mRNA expression
of CEBPG was low in proliferating C2C12 myoblasts, tended to be
higher in differentiated myotubes and demonstrated a slightly later
peak around day 3 of differentiation (P < 0.001; Fig. 2h). ATF5 is a
transcription factor that has previously been reported to tran-
scriptionally regulate similar gene targets as ATF4 in response to stress
associated with nutrient deprivation [26]. Similar to ATF4, ATF5 forms
a heterodimer with different C/EBPs that binds to regulate transcription
of target genes. Pearson's r coefficient indicated positive correlations
between ATF5 and PCK2 (r=0.692), ASNS (r=0.741), PHGDH
(r=0.504), PSAT1 (r=0.664), PSPH (r=0.715) and SESN2
(r=0.922), whereas a negative correlation was observed between
Table 1
Forward and reverse murine primer sequences for QPCR.
Gene Forward primer (5’ → 3′) Reverse primer (5’ → 3′)
ASNS GAAGGAACTCTACCTGTTTGATGTT GGGACTCTCAGTTCGAGACCGT
ATF5 GAGAGGGAGGTCTCGTGTACGT GATGGACTGGATAGGAAAGTGGAA
CEBPG GAGGCGCAGGTACATGTGAA CCTTTGCCAACACAGAATAGGTAGA
ENO3 GCCTGCTCCTGAAGGTCAAC TGCAAGTTTACAGGCCTGGAT
IDH2 TTGAGGCTGAGGCTGCTCAT CCGGCCCTTCTGGTGTT
PC CCAACTTCGCTCACGTCTCA GCGTTCTCATAGCCTACCTGCTT
PCK2 GCAGAGCACATGCTGATTTTG GGAAAGCAGCTGCCACGTA
PHGDH CGTGAACTTGGTGAACGCTAAG GTGGGAGGTGGTGACATTGAG
PSAT1 CGTGCTTCAGCATCTACGTCAT GCCCCGCCGTTGTTCT
PSPH GGCATAAGGGAGCTGGTAAGC GCCACCAGAGATGAGGAACAC
SESN2 TCAGCGAGGTCAACAAGTTACTG CAAGGCCTGGATATGCTCCTT
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ATF5 and CEBPG (r=−0.796). This suggests that ATF5 might act as a
possible transcriptional regulator of this group of genes during
C2C12 cell myogenic differentiation; but CEBPG is unlikely to be a
transcriptional regulator of these genes.
The next step was to investigate the association between the mRNA
expression of this group of genes with muscle cell hypertrophic growth
in vitro. This was performed by treating C2C12 cells with dbcAMP, to
mimic the downstream signalling effects of β2-AR stimulation, both at
the onset of differentiation (from day 0) and once myotubes were suf-
ficiently differentiated (from day 4).
3.2. Treatment of C2C12 cells with dbcAMP from day 0 of differentiation
Treatment with dbcAMP from day 0 resulted in larger myotubes
after 2 and 5 days (Fig. 3a). After 5 days the cells were sparser but much
larger myotubes were observed, as well as round bulging cells, sug-
gesting that cells had migrated to form more mature myotubes, but had
also started to contract off the plate.
There was no significant time× treatment interaction for myogenin
mRNA (P > 0.1), but as seen previously myogenin was low in pro-
liferating myoblasts, peaked around day 2 and then decreased with time
(P < 0.001; Fig. 3b), while dbcAMP treatment significantly increased
myogenin mRNA (P < 0.001). There were significant time× treat-
ment interactions for relative mRNA expression of MyHC-I, MyHC-IIB
and PC (all P < 0.001). Bonferroni post-hoc tests were performed and
results can be found in Table A.2. As differentiation was initiated
MyHC-I mRNA was upregulated, demonstrating a similar trend to
myogenin, but with an additional large induction at day 6 (Fig. 3c).
Treatment with dbcAMP from day 0 appeared to reduce this spike in
MyHC-I mRNA at day 6 compared to cells treated with vehicle control.
As observed previously, MyHC-IIB mRNA expression progressively in-
creased with myogenic differentiation (Fig. 3d). Interestingly, PC
mRNA expression showed a very similar pattern to MyHC-IIB mRNA
(Fig. 3e) and treatment with dbcAMP resulted in a dramatic induction
of both PC and MyHC-IIB mRNA from day 2 and day 3 of differentiation
respectively. Strong positive correlations were observed between
MyHC-IIB and PC mRNA expression in cells treated from day 0 with
either vehicle control (r=0.984) or dbcAMP (r=0.946). Additional
Pearson's r correlation coefficients can be found in Table A.3.
There were significant time× treatment interactions for expression
of both IDH2 (P=0.021; Fig. 3f) and ENO3 mRNA (P=0.002;
Fig. 3g). Treatment with dbcAMP from day 0 generally increased ENO3
mRNA at most time-points, whereas there was an inconsistent effect on
IDH2. As in the previous experiment, expression of PCK2, PHGDH,
PSAT1 and ASNS mRNA were generally higher in proliferating myo-
blasts than differentiated myotubes and there was again a peak at day 2
(all P < 0.01). Unexpectedly, dbcAMP treatment from day 0 reduced
PCK2 and PHGDH mRNA compared to the control (P < 0.01; Fig. 4a
Fig. 1. Endogenous mRNA expression profiles of genes associated with myogenesis and metabolism during C2C12 myogenic differentiation.
(a) Bright field photographs show C2C12 cells on days 0, 2 and 8 of differentiation. Photographs were captured at 6.3X magnification. Scale bar: 100 μm. Day 0
indicates the switch from growth to differentiation media. Relative mRNA expression of (b) Myf5, (c) myogenin, (d) myosin heavy chain (MyHC)-I, (e) MyHC-IIB, (f)
isocitrate dehydrogenase-2 (IDH2), (g) enolase-3 (ENO3) and (h) pyruvate carboxylase (PC) were normalised to OliGreen® as a measure of total cDNA. Data is means
(n=4) ± SEM. Significant differences between individual time-points and day 0 of differentiation are indicated: P < 0.05 (*), P < 0.01 (**) and P < 0.001
(***).
M.C. Brearley, et al. Biochemistry and Biophysics Reports 20 (2019) 100694
4
Fig. 2. Endogenous mRNA expression profiles of serine biosynthesis and integrated stress response genes during C2C12 differentiation.
Relative mRNA expression of (a) phosphoenolpyruvate carboxykinase-2 (PCK2), (b) asparagine synthetase (ASNS), (c) phosphoglycerate dehydrogenase (PHGDH),
(d) phosphoserine aminotransferase-1 (PSAT1), (e) phosphoserine phosphatase (PSPH), (f) sestrin-2 (SESN2), (g) activating transcription factor-5 (ATF5) and (h)
CCAAT/enhancer binding protein (CEBPG) were normalised to OliGreen® as a measure of total cDNA. Data is means (n=4) ± SEM. Significant differences between
individual time-points and day 0 of differentiation are indicated: P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***).
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and c) and had no effect on ASNS or PSAT1 mRNA (P > 0.1; Fig. 4b
and d).
Since treatment with dbcAMP from day 0 did not induce the ex-
pected coordinate upregulation of these genes, the next experiment
used C2C12 cells differentiated for 4 days prior to treatment with
dbcAMP.
3.3. Treatment of C2C12 cells with dbcAMP from day 4 of differentiation
Treating C2C12 myotubes with dbcAMP from day 4 of differentia-
tion gave rise to sparser C2C12 myotubes as a result of clumping after 2
and 4 days of treatment (Fig. 5a). There appeared to be fewer myotubes
per field of view, possibly due to migration of cells or, more likely, loss
of mature myotubes due to them contracting off the plate. There was a
significant time× treatment interaction for expression of myogenin
and MyHC-I mRNA (both P < 0.01). Bonferroni post-hoc tests were
performed and results can be found in Table A.4. Myogenin mRNA
showed a similar pattern as observed previously, but the more extensive
time-course identified two less prominent peaks around days 6 and 8,
which dbcAMP treatment from day 4 further induced (Fig. 5b). This
would appear to suggest multiple rounds of differentiation. MyHC-I
mRNA showed a similar trend as previously reported, but with the
addition of a spike in expression at day 4 a.m. followed by a decrease
then a gradual increase up to day 8. Treatment with dbcAMP from day
4 of differentiation reduced MyHC-I mRNA, particularly between days 6
p.m. and 8 p.m.
There was a significant time× treatment interaction for MyHC-IIB
mRNA (P < 0.001; Fig. 5d), but not PC mRNA (P=0.44; Fig. 5e). As
expected, expression of both MyHC-IIB and PC (P=0.0014) was low in
proliferating myoblasts and generally increased during differentiation.
Although less dramatic than treatment from day 0, there was a sig-
nificant increase in MyHC-IIB mRNA on days 6 (a.m.) and 7 (p.m.)
following dbcAMP treatment from day 4 (time× treatment interaction
P < 0.001), whereas there was no effect of dbcAMP on PC mRNA
(P=0.157). There was a significant time× treatment interaction for
ENO3 mRNA (P=0.04; Fig. 5g), but not IDH2 (P > 0.05; Fig. 5f). As
Fig. 3. Effect of dbcAMP treatment from day 0 of differentiation on C2C12 cells and mRNA expression.
(a) Bright-field images captured at days 2 and 5 of treatment with 1mM dbcAMP or vehicle control (water) from day 0 of differentiation. Photographs were captured
at 6.3X magnification. Scale bar: 100 μm. Relative mRNA expression of (b) myogenin, (c) myosin heavy chain (MyHC)-I isoform, (d) MyHC-IIB, (e) pyruvate
carboxylase (PC), (f) IDH2 and (g) ENO3 were normalised to OliGreen® as a measure of total cDNA. Data is means ± SEM for n=6 (day −1), n=5 (day 0), n=4
(day 2, 4 & 5 a.m.; day 3 dbcAMP a.m.) or n=3 (day 1 a.m. & p.m.; day 2, 3, 4, 5 & 6 p.m.; day 3 control a.m.). #P < 0.001 (time× treatment interaction). Ω
P < 0.01 (time effect). Φ P < 0.01 (treatment effect). ↑ indicates the start of treatment. See Table A.2 for Bonferroni post-hoc multiple comparisons.
Fig. 4. Effect of dbcAMP treatment from day 0 on serine biosynthesis and integrated stress response genes.
Relative mRNA expression of (a) PCK2, (b) ASNS (c) PHGDH and (d) PSAT1 following treatment with 1mM dbcAMP or vehicle control (water) from day 0 of
differentiation were normalised to OliGreen® as a measure of total cDNA. Data is mean ± SEM for. n=6 (day −1), n=5 (day 0), n=4 (day 2, 4 & 5 a.m.; day 3
dbcAMP a.m.) or n=3 (day 1 a.m. & p.m.; day 2, 3, 4, 5 & 6 p.m.; day 3 control a.m.). Ω P < 0.01 (time effect). Φ P < 0.01 (treatment effect). ↑ indicates the start
of treatment.
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previously observed, ENO3 mRNA increased with differentiation, but
this was reduced with dbcAMP; while IDH2 mRNA decreased with
differentiation (P < 0.001), and there was no effect of dbcAMP
(P=0.145).
There were significant time× treatment interactions (P < 0.01)
for expression of PCK2, ASNS, PHGDH and PSAT1 mRNA (Fig. 6a-d).
Bonferroni post-hoc tests were performed and results can be found in
Table A.4. As observed previously, mRNA expression was higher in
proliferating myoblasts compared to differentiated myotubes and there
was a peak at day 2, but also a later peak between days 6 and 7 of
differentiation (similar to myogenin expression). Treatment with
dbcAMP from day 4 appeared to reduce PHGDH and PSAT1 mRNA
levels between days 5 and 7 but had little effect on PCK2 or ASNS
mRNA. Pearson's r correlation coefficients can be found in Table A.5.
4. Discussion
This study involved extensive time-course experiments to determine
changes in endogenous gene expression during C2C12 myogenic dif-
ferentiation. It made the novel observation of a prominent day 2 peak in
mRNA expression for a group of genes (PCK2, PHGDH, PSAT1, PSPH,
ASNS, SESN2, ATF5) that had previously been shown to have a co-
ordinate increase in expression associated with BA-induced muscle fibre
hypertrophy in pigs [5,6]. The peak in endogenous expression at day 2
coincided with the peak in myogenin mRNA, therefore indicating a
potential role for these genes in myogenic differentiation. Although it
was already known that dbcAMP induced hypertrophy in C2C12 cells,
this is the first time that the dramatic induction and strong positive
correlation between MyHC-IIB and PC mRNA expression has been re-
ported in response to dbcAMP treatment from day 0 of differentiation.
The transcription factor ATF4 has been described as regulating the
expression of various genes, including PCK2, PHGDH, PSAT1, PSPH,
ASNS, SESN2 and ATF5 [16,27]. However, in BA treated pigs no change
in ATF4 gene expression was detected, therefore ATF4 was not mea-
sured in the current study. As seen previously in BA-stimulated muscle,
there was an increase in the mRNA expression of the transcription
Fig. 5. Effect of dbcAMP treatment from day 4 of differentiation on C2C12 cells and mRNA expression.
(a) Bright-field images captured after 2 and 4 days of treatment with 1mM dbcAMP or vehicle control (water) from day 4 of differentiation. Photographs were
captured at 6.3X magnification. Scale bar: 100 μm. Relative mRNA expression of (b) myogenin, (c) MyHC-I, (d) MyHC-IIB, (e) PC, (f) IDH2 and (g) ENO3 were
normalised to OliGreen® as a measure of total cDNA. Data is means ± SEM for. n=6 (day 0; day 8 p.m.), n=5 (days −1, 1, 2, 3; day 4 a.m.), n=4 (days 7 a.m., 8
a.m.) or n=3 (day 4 p.m., 7 p.m.; days 5, 6 a.m. and p.m. for each). #P < 0.001 (time× treatment interaction). Ω P < 0.01 (time effect). ↑ indicates the start of
treatment. See Table A.4 for Bonferroni post-hoc multiple comparisons.
Fig. 6. Effect of dbcAMP treatment from day 4 on serine biosynthesis and integrated stress response genes.
Relative mRNA expression of (a) PCK2, (b) ASNS, (c) PHGDH and (d) PSAT1 following treatment with 1mM dbcAMP or vehicle control (water) from day 4 of
differentiation were normalised to OliGreen® as a measure of total cDNA. Data is means ± SEM for n=6 (day 0; day 8 p.m.), n=5 (days −1, 1, 2, 3; day 4 a.m.),
n=4 (days 7 a.m., 8 a.m.) or n=3 (day 4 p.m., 7 p.m.; days 5, 6 a.m. and p.m. for each). #P < 0.001 (time× treatment interaction). ↑ indicates the start of
treatment. See Table A.4 for Bonferroni post-hoc multiple comparisons.
M.C. Brearley, et al. Biochemistry and Biophysics Reports 20 (2019) 100694
9
factor, ATF5, coincident with an increase in PCK2, PHGDH, PSAT1,
PSPH, ASNS and SESN2 at day 2 of differentiation in C2C12 cells. The
coordinate upregulation of the same group of genes observed in this
study and in response to BA treatment in the pig trial [5,6] indicates a
potential role in myogenic differentiation in vitro, as well as hyper-
trophic muscle growth in vivo. Myogenic differentiation involves dra-
matic morphological changes, where mononucleated myoblasts fuse to
form multinucleated myotubes. A transient peak between days −1 and
2 for a large group of genes related to cell adhesion, cell-cycle arrest
and cell fusion has previously been reported [28], highlighting this as a
key time for the switch from a proliferative to differentiated state. This
transition is likely to be a highly demanding time, therefore the syn-
chronous peak in PEPCK-M, serine biosynthesis and other metabolic
genes might demonstrate the route by which biosynthetic demands are
met. Muscle hypertrophy mainly occurs due to the recruitment and
fusion of satellite cells, as well as the associated changes in the rate of
protein synthesis, resulting in increased muscle mass [29]. Therefore,
the induction of these metabolic genes observed during myogenic dif-
ferentiation (at day 2) in vitro and in BA-stimulated muscle in vivo [5,6],
might be associated with the biosynthetic demands related to cell fusion
and hypertrophic growth. By upregulating this group of genes, we
postulate that the flux of carbons through glycolysis and TCA cycle is
subsequently diverted towards the synthesis of molecules that may
become limiting (e.g. serine, asparagine, sphingolipids, etc.), rather
than being used to produce lactic acid or being completely oxidised for
the generation of ATP.
Although hypertrophic growth was observed in C2C12 cells treated
with dbcAMP from day 0 and day 4 of differentiation, associated with
the induction of myogenin and MyHC-IIB mRNA, dbcAMP treatment
had little effect on the expression of PCK2, PHGDH, PSAT1 and ASNS
mRNA in vitro. Treatment from day 0 induced an increase in ENO3
mRNA, followed by the dramatic induction of MyHC-IIB mRNA, which
reflects observations in the pig trial [5], and coupled with a similar
induction of PC mRNA. However, this was not observed when differ-
entiated C2C12 myotubes were treated with dbcAMP from day 4. The
difference in responses might demonstrate a species difference between
pigs and mice, but it might also relate to the treatment used. The BA
response in vivo involves activation of the β2-adrenergic receptor (β2-
AR), which leads to downstream signalling mechanisms and increased
intracellular cyclic AMP (cAMP) [30]. As mentioned previously,
C2C12 cells are not responsive to BA treatment [22], therefore the ad-
dition of dbcAMP mimics the downstream response to BA by increasing
intracellular cAMP, but without activating the β2-AR. Bypassing the β2-
AR prevents downregulation of the receptor and therefore inhibition of
the response, however alternative signalling pathways that branch from
β2-AR activation, independent of cAMP, may also be bypassed. This
might indicate that the upregulation in this group of genes resulting in
muscle hypertrophic growth in pigs [5,6] is via another pathway, such
as Ras/MAPK or PI3K/AKT [31]; however, further work is needed to
prove or disprove this hypothesis.
As C2C12 cells progressed through myogenic differentiation we
observed similar changes in mRNA expression for Myf5 and myogenin
as reported previously [32,33]. This was associated with a decrease in
IDH2 and an increase in ENO3 mRNA levels, suggesting a change in
metabolic potential to support glycolytic metabolism and would agree
with the observation of increased fast-glycolytic MyHC-IIB isoform
mRNA as C2C12 myotubes mature. However, it has previously been
reported that C2C12 cells become more oxidative as they differentiate,
as indicated by an increased number and remodelling of the mi-
tochondria [34,35]. This is supported by observations using Seahorse
technology [36], which indicates some discrepancy between the direct
metabolic and indirect gene expression data. Seahorse technology
measures glycolysis based on the production of lactic acid, while oxi-
dative metabolism is measured as oxygen consumption, but these
measurements may not be truly representative of the flux of carbons
through glycolysis and oxidative metabolism, especially given the other
observed changes in gene expression (e.g. serine and asparagine bio-
synthesis). A good example of this are cancer cells as they demonstrate
a dependence on increased glycolytic flux, but not all of the glycolytic
flux results in lactate production [37]. Cancer cells alter their metabolic
profile in order to sustain proliferation and growth by diverting gly-
colytic intermediates towards biosynthetic pathways, such as serine
biosynthesis for protein synthesis and other macromolecules
[10,15,38,39]. As lactate is not produced, Seahorse technology is un-
able to account for glycolytic flux feeding into these different pathways,
and therefore most likely underestimates actual glycolytic flux. C2C12
myoblasts are highly proliferative so possibly demonstrate similar me-
tabolic characteristics to generate biosynthetic intermediates and sus-
tain myogenic differentiation, which would also be overlooked by
Seahorse technology. Therefore we hypothesise that this glycolytic flux
feeding into other biosynthetic pathways during proliferation could be
maintained or even increased during myogenic differentiation, to meet
the demands of C2C12 myoblast fusion and myotube maturation.
5. Conclusion
In summary, the same genes (PCK2, PHGDH, PSAT1, PSPH, ASNS,
SESN2, ATF5) that were upregulated with BA-induced hypertrophy in
pigs [5,6] demonstrated a coordinated upregulation in endogenous
mRNA expression at day 2 of differentiation in C2C12 cells, that coin-
cided with the peak in myogenin mRNA. This day 2 peak appears to be
a key point of myogenic differentiation, where proliferative myoblasts
become post-mitotic, and differentiate, potentially leading to a shift in
biosynthetic demand. Therefore, this coordinated induction of meta-
bolic gene expression may help sustain requirements during cell fusion
and hypertrophy induced by BA treatment. The effects of dbcAMP
treatment on mRNA expression in C2C12 cells were not the same as BA-
induced effects on pig muscles. We hypothesise that these differences
indicate that physical binding of a BA to the β2-AR is essential to ac-
tivate alternative downstream signalling pathways (i.e. those not acti-
vated via cAMP) and induce the observed coordinate upregulation of
these metabolic genes in vivo [5,6].
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